Use and significance of anti-CCP autoantibodies in rheumatoid arthritis
Open Access
- 27 September 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (1) , 20-25
- https://doi.org/10.1093/rheumatology/kei111
Abstract
One of the most common autoimmune diseases is rheumatoid arthritis (RA), affecting 0.5–1% of the population. This systemic disease is marked by chronic inflammation of synovial joints, which leads to destruction of cartilage and bone and eventually to disability of the patient [1]. Though not directly life-threatening, RA severely affects the quality of life of a patient and also has major economic consequences for society. Therefore, every attempt should be made to prevent the erosive processes to occur. Currently, the classification of RA relies mainly on the criteria described by the American College of Rheumatology (ACR) [2]. These criteria, originally formulated 50 yr ago and last adjusted in 1987, are based mainly on clinical parameters. Since these parameters are often only sufficiently fulfilled when the damaging effects of the inflammatory process are already in progress, this set of criteria is not very suitable for the early diagnosis of RA [3].Keywords
This publication has 68 references indexed in Scilit:
- A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritisAnnals of the Rheumatic Diseases, 2005
- Proteomic: New advances in the diagnosis of rheumatoid arthritisClinica Chimica Acta; International Journal of Clinical Chemistry, 2005
- Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti–cyclic citrullinated peptide antibodyArthritis & Rheumatism, 2004
- The presence of citrullinated proteins is not specific for rheumatoid synovial tissueArthritis & Rheumatism, 2004
- Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvementAnnals of the Rheumatic Diseases, 2004
- Second generation anti‐cyclic citrullinated peptide (anti‐CCP2) antibodies can replace other anti‐filaggrin antibodies and improve rheumatoid arthritis diagnosisScandinavian Journal of Rheumatology, 2004
- Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseasesAnnals of the Rheumatic Diseases, 2004
- Detection of antibodies to deiminated recombinant rat filaggrin by enzyme‐linked immunosorbent assay: A highly effective test for the diagnosis of rheumatoid arthritisArthritis & Rheumatism, 2002
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988